SLRN ACELYRIN Accounting Capitalization

The market trend for Acelyrin, Inc. (SLRN) shares is fixed at 0.40. The company's supply stability is ensured by strict temperature control during the transportation of biologics to medical centers. The business relies on the creation of small proteins for the therapy of skin pathologies that overcome tissue barriers. However, a lack of sales and challenges with clinical trials have led to a partial investor exodus, and development is currently focused on patents under FDA supervision.

SLRN ACELYRIN Inc. Book Capitalization (02/21/2024 - 05/31/2025)

Metric breakdowns and analytics for ACELYRIN (SLRN)

- price and consensus price forecast:
Price Performance Chart ACELYRIN Inc.|SLRN - Price Target Chart
- market capitalization data:
Market Capitalization Acelyrin Inc.|SLRN - Total Company Value
- book capitalization data:
Share Book Value ACELYRIN|SLRN - Book Capitalization|Market Value to Book Value acelyrin.com|SLRN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Acelyrin, Inc.|SLRN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Acelyrin Inc.|SLRN - Company Debts|Debt to Book Value Acelyrin Inc.
Fundamental valuation:SLRN - ACELYRIN Inc.

Book value reflects the total value of net assets, determining the fundamental stability of the business through the difference between all assets and liabilities. Analysis of the book equity chart allows for tracking the real growth of resources at Acelyrin, Inc. (SLRN), which is critical for assessing the investment efficiency in developing high-margin drugs for the treatment of autoimmune diseases.

Competitor analysis for Acelyrin, Inc.

HLN: Accounting Value of Company|Company Book Value Kenvue Inc.|VRNA (veronapharma.com) - Accounting Capitalization|Company Book Value Jyong Biotech MENS|Net Asset Value Ligand Pharmaceuticals Incorporated|Amneal Pharmaceuticals Inc (AMRX) - Book Capitalization|Accounting Value of Company Perrigo Corp (PRGO)|Book Capitalization ALVO (Alvotech)|liquidia.com - Book Capitalization|Company Book Value Galapagos (GLPG)|ANIP: Accounting Value of Company|MNKD (MannKind Corp.) - Company Book Value|Amphastar Corp (AMPH) - Company Net Assets|PCRX (Pacira BioSciences) - Book Capitalization|Book Capitalization ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Company Net Assets|Accounting Value of Company AQST (Aquestive Therapeutics Inc)|SCPH: Company Book Value|TECX - Total Stockholders' Equity|Company Net Assets Tonix Pharmaceuticals TNXP|SXTC - Total Net Assets|Book Capitalization eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Accounting Value of Company|Book Capitalization EXOZ (Invizyne Technologies, Inc.)|Total Stockholders' Equity ORMP|Entera Bio Ltd. (ENTX) - Company Book Value|Accounting Value of Company ipatherapeutics.com (HYFT)|Book Capitalization ABVC (ABVC BioPharma, Inc.)|Book Capitalization Cumberland Pharmaceuticals Inc CPIX|QNTM: Book Capitalization|FGEN - Company Net Assets|Book Capitalization TELO|RANI (Rani Therapeutics Holdings, Inc.) - Total Stockholders' Equity|Company Book Value Synergy CHC Corp.|Company Book Value Rallybio Corp. (RLYB)|Lexaria Bioscience - Company Net Assets|Total Stockholders' Equity PULM (Pulmatrix Corporation)|Company Book Value Pheton Holdings|Accounting Value of Company Aptorum Group Ltd APM|Book Capitalization LYRA (Lyra Therapeutics)|IBO: Book Valuation of Business|Company Book Value tnfpharma.com|Accounting Capitalization cbdMD|PRFX - Company Net Assets|Accounting Value of Company Auris Medical|LIPO (Lipella Pharmaceuticals, Inc.) - Book Capitalization|Book Valuation of Business OPTN (OptiNose Inc)|PIRS - Company Book Value|Accounting Capitalization Procaps Group Corp PROC|PTPI: Book Capitalization|qlsyy.net (QLI) - Company Net Assets|TFF Pharmaceuticals, Inc. - Company Net Assets